title: Patient preferences for adherence to treatment for osteoarthritis: the MEdication Decisions in Osteoarthritis Study (MEDOS).
abstract: BACKGROUND
  Often affecting knee joints, osteoarthritis (OA) is the most common type of arthritis and by 2020 is predicted to become the fourth leading cause of disability globally. Without cure, medication management is symptomatic, mostly with simple analgesics such as acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs), and glucosamine sulfate. Adherence to arthritis medications is generally low. Intentional non-adherence, that is deliberate decision-making about the use of analgesics, occurs in OA patients. To date, a limited number of studies have explored medication-taking decisions in people with OA nor the extent to which individuals' trade off one treatment factor for another in their decision-making using quantitative techniques. This study aimed to estimate the relative influence of medication-related factors and respondent characteristics on decisions to continue medications among people with symptomatic OA.
  
  
  METHODS
  A discrete choice experiment (DCE) was conducted among participants attending end-of-study visits in the Long-term Evaluation of Glucosamine Sulfate (LEGS) study (ClinicalTrials.gov ID: NCT00513422). The paper-based survey was used to estimate the relative importance of seven medication specific factors (pain efficacy, mode of action, dose frequency, treatment schedule, side effects, prescription, and out-of-pocket costs) and respondent characteristics on decisions to continue medications.
  
  
  RESULTS
  188 (response rate 37%) completed surveys were returned. Four of the seven medication factors (side effects, out-of-pocket costs, mode of action, treatment schedule) had a significant effect on the choice to continue medication; patient characteristics did not. Assuming equivalent pain efficacy and disease-modifying properties for glucosamine, the positive relative likelihood of continuing with sustained-release acetaminophen was equivalent to glucosamine. By contrast, the negative relative likelihood of NSAID continuation was mostly driven by the side effect profile. The predicted probability of continuing with glucosamine decreased with increasing out-of-pocket costs.
  
  
  CONCLUSIONS
  This study has characterised the complexity of medication-taking decisions that potentially underpin intentional non-adherent behaviour for people with symptomatic OA. In particular, medication risks and cost were important and ought to be borne into considerations in interpreting clinical trial evidence for practice. Ultimately addressing these factors may be the way forward to realising the full potential of health and economic benefits from the efficacious and safe use of OA medications.
authors: Faculty of Pharmacy, The University of Sydney, Camperdown, Sydney, Australia. thar7910@uni.sydney.edu.au
authors: Tracey-Lea
authors: TL
authors: Laba
authors: Jo-anne
authors: JA
authors: Brien
authors: Marlene
authors: M
authors: Fransen
authors: Stephen
authors: S
authors: Jan
mesh_terms: D000082:Acetaminophen / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002755:Choice Behavior; D005260:Female; D005944:Glucosamine / Q000627:therapeutic use; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008297:Male; D055118:Medication Adherence / Q000523:psychology*; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D059408:Pain Management; D010147:Pain Measurement; D010358:Patient Participation
chemical_list: D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000082:Acetaminophen; D005944:Glucosamine
references: Value Health. 2011 Jun;14(4):403-13
references: 21669364
references: Arthritis Rheum. 2004 Apr 15;51(2):210-4
references: 15077261
references: Int J Nurs Stud. 2007 Nov;44(8):1468-77
references: 16973166
references: Med Care. 1998 May;36(5):728-39
references: 9596063
references: Health Econ. 2002 Jul;11(5):457-65
references: 12112494
references: Health Econ. 2007 Aug;16(8):827-40
references: 17238222
references: Prev Med. 2002 Aug;35(2):166-73
references: 12200102
references: Arch Intern Med. 2005 Aug 8-22;165(15):1749-55
references: 16087823
references: Osteoarthritis Cartilage. 2013 Feb;21(2):289-97
references: 23182815
references: J Rheumatol. 2004 Mar;31(3):591-3
references: 14994409
references: BMC Fam Pract. 2012 Jun 20;13:61
references: 22715853
references: Age Ageing. 2011 Mar;40(2):254-9
references: 21187281
references: J Rheumatol. 2004 Feb;31(2):344-54
references: 14760807
references: BMC Musculoskelet Disord. 2009 Nov 10;10:137
references: 19903350
references: Health Technol Assess. 2009 Nov;13(52):1-148
references: 19903416
references: Ethn Dis. 2004 Autumn;14(4):558-66
references: 15724776
references: Curr Med Res Opin. 2011 Feb;27(2):295-302
references: 21142617
references: Int J Technol Assess Health Care. 1999 Summer;15(3):443-57
references: 10874373
references: Health Econ. 2004 Apr;13(4):397-402
references: 15067675
references: J Rheumatol. 1999 Dec;26(12):2664-74
references: 10606380
references: Drugs Aging. 2007;24(7):573-80
references: 17658908
references: Health Econ Policy Law. 2009 Oct;4(Pt 4):527-46
references: 19715635
references: Pharmacoeconomics. 2008;26(8):661-77
references: 18620460
references: Rheumatology (Oxford). 2000 Apr;39(4):448-9
references: 10817785
references: J Rheumatol. 2003 Jan;30(1):44-54
references: 12508389
references: Rheumatology (Oxford). 2004 Mar;43(3):337-45
references: 14585925
references: Arthritis Care Res (Hoboken). 2012 Apr;64(4):465-74
references: 22563589
references: Ann Pharmacother. 1999 Nov;33(11):1154-9
references: 10573311
references: Arthritis Rheum. 2006 Apr 15;55(2):272-8
references: 16583418
references: Appl Health Econ Health Policy. 2003;2(1):55-64
references: 14619274
references: Respirology. 2007 Jan;12(1):127-36
references: 17207038
references: Best Pract Res Clin Rheumatol. 2001 Oct;15(4):645-56
references: 11567545
references: Arthritis Care Res (Hoboken). 2011 Sep;63(9):1280-6
references: 21671423
references: Bull World Health Organ. 2003;81(9):646-56
references: 14710506
references: Qual Health Res. 2011 Feb;21(2):214-22
references: 20798264
references: Arch Intern Med. 2004 Jun 28;164(12):1299-304
references: 15226163
references: Health Econ. 2007 Nov;16(11):1185-204
references: 17304501
references: PLoS One. 2012;7(7):e41540
references: 22859995
references: J Rheumatol. 2007 Jul;34(7):1569-75
references: 17552039
references: N Engl J Med. 2005 Aug 4;353(5):487-97
references: 16079372